Apogee Therapeutics Finalizes $402.5M Public Offering at $70.00/Share
APGE has more than doubled off its 52-week low of $26.2 on elevated volume (3.3× avg).
Summary
Apogee Therapeutics finalized its public offering, selling 5.75 million shares at $70.00 per share, raising approximately $377.4 million in net proceeds to fund operations.
Key Events · Financing and Capital Events · APGE
-
Public Offering Finalized
Apogee Therapeutics entered into an underwriting agreement to sell 5,000,000 shares of common stock.
-
Over-Allotment Option Fully Exercised
The underwriters fully exercised their option to purchase an additional 750,000 shares, bringing the total to 5,750,000 shares.
-
Offering Price and Proceeds
The shares were sold at a public offering price of $70.00 per share, generating approximately $377.4 million in net proceeds.
-
Expected Closing Date
The offering is expected to close on March 26, 2026.
Analysis · APGE · Life Sciences
This 8-K filing finalizes the terms and pricing of the previously announced public offering, following positive Phase 2 clinical trial data. Apogee Therapeutics sold 5.75 million shares, including the full exercise of the underwriters' over-allotment option, at $70.00 per share. While the offering is dilutive and priced at a discount to the current market price, it successfully raises approximately $377.4 million in net proceeds. For a life sciences company, securing substantial capital is crucial for advancing its clinical pipeline and extending its operational runway, significantly strengthening its balance sheet.
At the time of this filing, APGE was trading at $78.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $26.20 to $85.04. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.